Does Reimbursement Affect Physician Decision Making?
Cancer care is expensive, with large expenditures being associated with new technologies and Pharmaceuticals, supportive care modalities, and terminal care.1 Almost one third of an individual’s lifetime medical costs are incurred during the last several months of life. The high costs of cancer care raise important issues related to access to new cancer technologies. In particular, are all cancer patients equally likely to receive the expensive new medical developments? What is the relationship between patient’s socioeconomic status and type of health insurance and the use of cancer therapies? Do financial arrangements between physicians and insurers affect the type and intensity of cancer care? Do these factors have an effect on the type, quality, and results of care in the clinical oncology setting?
KeywordsVeteran Affair Cancer Care Peripheral Blood Stem Cell Peripheral Blood Stem Cell Transplantation Manage Care Organization
Unable to display preview. Download preview PDF.
- 1.Smith TJ. Role of granulocyte and granulocyte macrophage colony stimulating factors in clinical practice: Balancing clinical and economic concerns. American Society of Clinical Oncology Educational Book. 35th Annual Meeting. 1999: 275-299.Google Scholar
- 7.Health News Daily. 1995. Half of US physicians are associated with risk insurance plans, Nov 13, p. 4.Google Scholar
- 13.American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: Evidence based clinical practice guidelines. J Clin Onc 1994; 12: 2471–2508.Google Scholar
- 14.Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines. J Clin On 1996; 14: 1957–1960.Google Scholar
- 15.Bennett CL, Smith TJ, Weeks JC et al. Use of hematopoietic colony stimulating factors: The American Society of Clinical Oncology Survey. J Clin Onc 1997; 14: 2511–2520.Google Scholar
- 16.Bennett CL, Somerfield M, Feinglass J, Smith TJ. Decrease in misuse/overuse of hematopoietic colony stimulating factors for solid tumors and lymphomas: Results from ASCO Surveys Related to the 1994 and 1996 ASCO CSF Guidelines. Proceedings of ASCO 1998; 17: 421a.Google Scholar
- 18.Bataladan P, Nelson E, Roberts J. Linking outcomes measurement to continual improvement: the serial “V” way of thinking about improving clinical care. Jt Comm J Qual Improv 1994; 20: 167–80.Google Scholar
- 20.Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen blockade with medical or surgical castration in advanced cancer: A meta-anlysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases 1999; 2: 4–8.PubMedCrossRefGoogle Scholar
- 24.Freeman MB, Vose JM, Bennett CL et al. Costs of Care for High-Dose Therapy and Autologous Transplantation for Non-Hodgkin’s Lymphoma: Results From the University of Nebraska Medical Center 1989 Through 1995; Bone Marrow Transplantation 1999; in press.Google Scholar
- 26.Welch HG. Valuing clinical strategies early in their development. Annals of Int Medl 16: 263–4; 1992.Google Scholar
- 28.Bennett CL, Waters TM, Stinson TJ et al. Valuing Clinical Strategies Early in Development: A Cost Analysis of Allogeneic Peripheral Blood Stem Cell Transplantation. Bone Marrow Transplantation 1999; in press.Google Scholar
- 29.Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of lenograstim-primved blood cell versus bone marrow allogeneic transplantation: Comparison of haematological recovery and socioeconomic evaluation. Proceedings ofthe American Society of Hematology 1998; 557a.Google Scholar
- 30.Bennett CL, Stinson TJ, Yang T, Lurain JR. The Effect of Reimbursement Policies on the Management of Medicare Patients with Refractory Ovarian Cancer. Sem Oncol 1999; 26(1) Suppl A:34–39.Google Scholar